CARVEDILOL PHOSPHATE (carvedilol phosphate) by Viatris (2) is beta-adrenoreceptor blocking activity is present in the s(−) enantiomer and alpha 1 -adrenergic blocking activity is present in both r(+) and s(−) enantiomers at equal potency. Approved for mild-to-severe chronic heart failure of ischemic, cardiomyopathic origin, usually in addition to diuretics and 13 more indications. First approved in 2018.
Drug data last refreshed 18h ago
beta-adrenoreceptor blocking activity is present in the S(−) enantiomer and alpha 1 -adrenergic blocking activity is present in both R(+) and S(−) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.
Worked on CARVEDILOL PHOSPHATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.